Sign Up For Life Science Leader Magazine

EXECUTIVE INTERVIEWS

Nora Therapeutics

This company’s novel and lonely development of a new fertility drug belies the industry’s current uninterest in the field.

More From Executive Interviews

THE CURRENT ISSUE

  • 3 Lessons Pharma Can Learn From ALS Ice Bucket Fever
    3 Lessons Pharma Can Learn From ALS Ice Bucket Fever

    Regardless of your opinion of the ALS Ice Bucket Challenge (IBC), which has catapulted the ALS Association’s (ALSA’s) charitable coffers to feverish heights, there are valuable business lessons from which pharma and biotech executives can learn.

  • Ask The Board
    Ask The Board

    Q: What was the most valuable leadership experience learned from working under an FDA manufacturing consent decree when you were at Genzyme?

  • Small Businesses Left Behind In Obamacare
    Small Businesses Left Behind In Obamacare

    The disastrous rollout of Healthcare.com for individuals attempting to purchase health insurance in Obamacare’s exchange is well-known, but a similar experience is still ongoing for small businesses. I experienced it myself this past month.

  • Is Discounting Services Good For Drug Development?
    Is Discounting Services Good For Drug Development?

    In the past decade of working in market research, I have witnessed the consumer behaviors of business and personal spending conflate. This has happened for a variety of reasons, the big influencers being the psychology of the sale and later, the economic downturn.

  • Moving Beyond The Batch
    Moving Beyond The Batch

    Best practices, opportunities, and challenges in continuous bioprocessing

  • Bayer HealthCare’s CoLaborator On Mission (Bay)
    Bayer HealthCare’s CoLaborator On Mission (Bay)

    The next suspense novel based on a new or imagined biotechnology breakthrough might consider borrowing its title from Bayer HealthCare’s incubator: “The CoLaborator.” More likely, pharma companies in the process of discerning ways to interact with life sciences start-ups would do well to study Bayer’s innovative model for collaboration.

  • As The Pharma Landscape Changes, So Should Your Partnering Approach
    As The Pharma Landscape Changes, So Should Your Partnering Approach

    The landscape for drug development is constantly changing. A technique or practice that was commonly accepted a few years ago may today be outdated and obsolete. This is true regarding all aspects of your business, including emerging markets, regulatory developments, and certainly partner relationships.

More Magazine Articles....

LIFE SCIENCE TRAINING INSTITUTE

More From LSTI

 UPCOMING EVENTS

Clinical Finance: Key Strategies to Stay in Control of Your Study Budget

October 28, 2014
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

The Top Method Validation Mistakes – And How to Avoid Them

October 29, 2014
1pm-2:30pm EDT, Online Training
Price:  $299 - Introductory Rate

AAPS Annual Meeting & Exposition

November 2 - 6, 2014
San Diego, CA

PACK EXPO International 2014

November 2 - 5, 2014
Chicago, IL
See All Events

LIFE SCIENCE SUPPLEMENTS

2014 -Trends In Clinical Research Outsourcing 2014 CMO Pharma Development & Manufacturing
 
Life Science Leader’s readership of pharmaceutical and biopharmaceutical executives have told us about their struggles in efficiently vetting potential CMO and CRO partners. In response to this input, Life Science Leader developed the Leadership Awards based on the industry leading research conducted by Nice Insight.
2014 CRO Leadership Awards 2013 CMO Leadership Awards
   
   
 

 

     
     
Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

VIEW THE DIGITAL EDITION